IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virologic response in HIV/HCV coinfection

2016 Liver International In press;

BACKGROUND & AIMS: IL15 is an essential cytokine in both innate and adaptive immune response against HCV infection. The aim was to analyze whether IL15 rs10833 is associated with liver disease severity and response to pegylated-interferon-alpha plus ribavirin (pegIFN-alpha/RBV) therapy in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. METHODS: A retrospective study was performed in 315 patients who started pegIFN-alpha/RBV therapy. Liver fibrosis stage was characterized in 286 patients. IL15 rs10833 and IL28B rs12980275 were genotyped by GoldenGate.The primary outcomes were: a) advanced liver fibrosis evaluated by liver biopsy (F3-F4) or transient elastography (liver stiffness values >/=9.5 Kpa); b) sustained virological response (SVR). The secondary outcome variable was the levels of serum biomarkers of inflammation. RESULTS: Patients with rs10833 AA genotype had increased odds of having advanced fibrosis (adjusted odds ratio (aOR)=2.30; p=0.019), particularly in males (aOR=2.24; p=0.040), patients with HCV-RNA /=500,000 IU/mL (aOR=3.92; p=0.007) and patients with IL28B rs12980275 AG/GG genotype (aOR=2.98; p=0.041). CONCLUSIONS: The presence of IL15 rs10833 AA genotype in HIV/HCV-coinfected patients was associated with advanced liver fibrosis, inflammation-related biomarkers and increased rates of SVR to pegIFN-alpha/RBV therapy. This article is protected by copyright. All rights reserved.

Pubmed : 26836972